Publication Name	World Journal of Clinical Cases
Manuscript ID	69187
Country	China

Received	2021-07-07 10:29
Peer-Review Started	2021-07-07 10:29
To Make the First Decision
Return for Revision	2021-07-26 02:24
Revised	2021-08-12 12:51
Second Decision	2021-10-11 08:28
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-10-14 02:39
Articles in Press	2021-10-14 02:39
Publication Fee Transferred
Edit the Manuscript by Language Editor	2021-10-05 01:37
Typeset the Manuscript	2021-11-15 02:19
Publish the Manuscript Online	2021-11-22 10:34

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Urology & Nephrology
Manuscript Type	Clinical Trials Study
Article Title	Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits
Manuscript Source	Unsolicited Manuscript
All Author List	Xiu Chen, Feng Zhao, Wei-Juan Pan, Jia-Mei Di, Wei-Nan Xie, Ling Yuan and Zhi Liu
ORCID	Author(s) ORCID Number Xiu Chen http://orcid.org/0000-0003-1129-3788 Feng Zhao http://orcid.org/0000-0003-4180-0656 Wei-Juan Pan http://orcid.org/0000-0002-4481-3228 Jia-Mei Di http://orcid.org/0000-0001-7859-8725 Wei-Nan Xie http://orcid.org/0000-0002-2814-4896 Ling Yuan http://orcid.org/0000-0003-1945-2392 Zhi Liu http://orcid.org/0000-0002-2326-9956
Funding Agency and Grant Number	Funding Agency Grant Number Anhui University Natural Science Research Project 2019 KJ2019A0094 Anhui University Natural Science Research Project 2019 KJ2019A0095 Huainan City "50 Science and Technology Stars" Innovation Team Project Scientific Research Platform of Huainan Science and Technology Bureau 2017G32
Corresponding Author	Zhi Liu, MD, Chief Doctor, Department of Nephrology, The First Affiliated Hospital of Anhui University of Science and Technology (The First People’s Hospital of Huainan), No. 203 Huaibin Road, Tianjiaan District, Huainan 232007, Anhui Province, China. hnsnk@163.com
Key Words	Paricalcitol; Hemodialysis; Secondary hyperparathyroidism; Drug efficacy; Drug safety
Core Tip	In this study, 40 patients with chronic renal failure were treated with paricalcitol for 24 wk. It was found that paricalcitol can significantly reduce intact parathyroid hormone, alkaline phosphatase and serum phosphate levels, and maintain a relatively stable serum calcium level. Therefore, paricalcitol is effective and safe in the treatment of hemodialysis patients with secondary hyperparathyroidism.
Publish Date	2021-11-22 10:34
Citation	Chen X, Zhao F, Pan WJ, Di JM, Xie WN, Yuan L, Liu Z. Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits. World J Clin Cases 2021; 9(33): 10172-10179
URL	https://www.wjgnet.com/2307-8960/full/v9/i33/10172.htm
DOI	https://dx.doi.org/10.12998/wjcc.v9.i33.10172

Full Article (PDF)	WJCC-9-10172.pdf
Full Article (Word)	WJCC-9-10172.docx
Manuscript File	69187_Auto_Edited-JLW-Filipodia.docx
Answering Reviewers	69187-Answering reviewers.pdf
Audio Core Tip	69187-Audio core tip.m4a
Biostatistics Review Certificate	69187-Biostatistics statement.pdf
Clinical Trial Registration Statement	69187-Clinical trial registration statement.pdf
Conflict-of-Interest Disclosure Form	69187-Conflict-of-interest statement.pdf
Copyright License Agreement	69187-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	69187-Grant application form(s).pdf
Signed Informed Consent Form(s) or Document(s)	69187-Informed consent statement.pdf
Institutional Review Board Approval Form or Document	69187-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate	69187-Language certificate.pdf
Peer-review Report	69187-Peer-review(s).pdf
Scientific Editor Work List	69187-Scientific editor work list.pdf